CD73 expression is critical to therapeutic effects of human endometrial regenerative cells in inhibition of cardiac allograft rejection in mice

Yonghao Hu1,2 | Dejun Kong1,2 | Yafei Qin1,2 | Dingding Yu1,2 | Wang Jin1,2 | Xiang Li1,2 | Yiming Zhao1,2 | Hongda Wang1,2 | Guangming Li1,2 | Jingpeng Hao2,3 | Baoren Zhang1,2 | Zhaoyan Pang4 | Hao Wang1,2

1Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China
2Tianjin General Surgery Institute, Tianjin, People’s Republic of China
3Department of Anorectal Surgery, The Second Hospital of Tianjin Medical University, Tianjin, People’s Republic of China
4Department of Nursing, China-Japan Friendship Hospital, Beijing, People’s Republic of China

Correspondence
Hao Wang, MD, PhD, Department of General Surgery, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300022, People’s Republic of China. Email: hwangca272@hotmail.com (preferred), Email: hwang1@tmu.edu.cn

Funding information
Tianjin Research Innovation Project for Postgraduate Students, Grant/Award Number: 2019YJS184; Tianjin Medical University Talent Fund; Natural Science Foundation of Tianjin, Grant/Award Number: 18JCJZDJC35800; Li Jieshou Intestinal Barrier Research Special Fund, Grant/Award Number: LJS_201412; Tianjin Application Basis and Cutting-Edge Technology Research Grant, Grant/Award Number: 14JCJZDJC35700; National Natural Science Foundation of China, Grant/Award Numbers: 81273257, 81471584

Abstract
The newly found mesenchymal-like endometrial regenerative cells (ERCs) have been proved to induce immune tolerance in cardiac allograft transplantation. However, the therapeutic mechanism is not clear. The present study was undertaken to investigate whether ecto-5'-nucleotidase (CD73) expression on ERCS is critical to cardiac allograft protection. C57BL/6 mouse recipients receiving BALB/c mouse cardiac allografts were treated with unmodified ERCs or anti-CD73 monoclonal antibodies (mAb) pretreated ERCs, respectively. It has been found that CD73 expression was critical to ERC-induced attenuation of graft pathology. The blockage of CD73 expression on ERCs was related to the percentage decline of tolerogenic dendritic cells (Tol-DCs), macrophages type 2 (M2), and regulatory T cells (Tregs). As compared with anti-CD73 mAb pretreated ERCs group, CD73 expressing ERCs significantly increased the level of anti-inflammatory cytokine IL-10 but decreased levels of pro-inflammatory cytokines including IFN-γ and TNF-α. In addition, CD73 expressing ERCs showed tissue protective function via the regulation of adenosine receptor expression which was related to the infiltration of CD4+ and CD8+ cells in the allografts. Furthermore, significant increase of A2B receptors in the cardiac allograft was also associated with CD73 expressing ERC-induced prolongation of cardiac allograft survival.

KEYWORDS
adenosine, allograft protection, cardiac transplantation, CD73, human endometrial regenerative cells

1 | INTRODUCTION

At present, organ transplantation has become the last resort for many life-threatening end-stage diseases. In 2018 alone, almost 35,000 patients received donated organs in the United States.1-3 However,
allograft rejection is still the major obstacle to successful transplantation. Although the discovery and application of immunosuppressive drugs has prolonged the graft survival time greatly, the limitations of these agents including rejection, infection, malignancy, and chronic graft dysfunction cannot be ignored.4–7 Under such conditions, it is in great need to find a new immunosuppressive drug which is safer and more effective.

Mesenchymal stem cells (MSCs) are a kind of multipotent stem cells which can differentiate to multiple lineages including adipocytes, osteoblasts, and chondrocytes.8 Data showed that MSCs did benefits to various diseases including autoimmune diseases, tissue injury, graft rejection, and so on.9–11 In the field of transplantation, the implication of MSCs has been proved to induce immune tolerance in animal models and have the potential of clinical application.12–15 However, the invasive harvesting procedure, limited proliferation capacity, and less availability are still the issues for MSCs clinical use in large quantities.15

To our excitement, the newly found endometrial regenerative cells (ERCs) are mesenchymal-like stromal cells which have the same properties as MSCs.16 Our previous studies have also demonstrated that ERCs performed therapeutic effects in bleomycin-induced pulmonary fibrosis,17 experimental colitis,18 renal ischemia reperfusion injury,19 and cardiac allograft rejection.20,21 In addition, ERCs have already been used clinically in four patients with multiple sclerosis.22 As a kind of therapeutic cells for clinical use and distinguished from MSCs, ERCs not only can be obtained noninvasively, but also ERCs have many other properties including abundant resources, highly proliferative rate, pluripotent differentiation activity, the ability to inhibit inflammatory responses, lack of immunogenicity, expandability to great quantities without karyotypic abnormalities, as well as the loss of differentiation ability and tumorigenesis.23–26 Although the safety and effectiveness of ERCs have been examined, the exact immunosuppressive mechanisms of ERCs still need to be fully elucidated.

Ecto-5′-nucleotidase (CD73) is a promising immunoregulatory molecule that can be expressed by various cells including B cells, T cells, neutrophils, natural killer cells, monocytes, and macrophages.27–31 Moreover, CD73 plays a critical role in purinergic signaling, which is the rate-limiting enzyme during the generation of extracellular adenosine (ADO).32 Furthermore, the ADO can bind with four ADO receptors namely A1, A2A, A2B, and A3 receptors.33,34 Thus, CD73 can not only show the biological functions by itself, but also performs effects by the generated ADO combing with ADO receptors. For example, in a heterotopic cardiac allotransplantation model, CD73 deficiency in either donors or recipients resulted in decreased graft survival.30 Meanwhile, in the field of anti-tumor therapy, CD73-ADO pathway has been proved to prevent excessive immune reactions and alleviate immune-mediated tissue damage through binding to A2A and A3 receptors.35,36

In the present study, we found that the multifunctional CD73 is highly expressed on the surface of ERCs. Resta et al also have demonstrated that murine CD73 is 94% identical to human CD73 at the amino acid level and the murine protein is remarkably similar to the human form.37 Given the CD73 expression and its immunoregulatory properties, we speculate that CD73 expression is critical for ERCs mediated cardiac allograft protection.

Significance statement

Endometrial regenerative cells (ERCs) are mesenchymal-like stromal cells derived from menstrual blood that are believed to be associated with tissue repair and immunoregulation. ERCs can be noninvasively obtained from abundant resource of menstrual blood; this process permits the large quantity cells needed in clinic. Ecto-5′-nucleotidase (CD73) is a key enzyme in purine metabolism. This study has demonstrated for the first time that CD73 expressed on ERCs plays a critical role in preventing graft rejection and prolonging cardiac allograft survival. The data generated will establish a framework for the development of clinical therapy that will enable the use of ERCs to achieve allograft acceptance.

2 | MATERIALS AND METHODS

2.1 | Isolation, culture, and detection of ERCs

All human ERCs used in this study were isolated from menstrual blood provided by healthy women volunteers who were 20 to 30 years old and the procedure was under the ethical approval from Tianjin Medical University (Tianjin, China). Cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin as described in the previous study of our team.28 In addition, the ERCs were cultured and expanded in a 37°C 5% CO2 incubator. After incubating for about 2 weeks, the ERCs could be harvested for further research. Then, the phenotype identification was detected by flow cytometry analysis and the expression of CD73 was further confirmed by fluorescence staining.

2.2 | Preparation of ERCs with anti-human CD73 monoclonal antibodies (mAb) and enzyme activity detection in vitro

Human ERCs were harvested from the 10 cm dishes and transferred to 96-well plates for 5 × 10⁴ cells per well on the first day. Next day, the culture supernate of cells was discarded and the plates were washed for three times by glycine buffer (75 mM glycine, 5 mM MgSO₄, pH 7.4).39 Then, the cells were incubated with anti-CD73 mAb (10 μg/mL), anti-CD73 isotype mAb (10 μg/mL) and equal glycine buffer at 37°C for 2 hours. After washing by glycine buffer for three times, the treated cells were used to detect the enzyme activity with the help of the PiColorLock Phosphate Detection Reagent (Expedeon, www.expedeon.com). In short, 0.1 mM ADO monophosphate was added to each well followed by 3 hours incubating at the temperature of 37°C. Then, 0.25 volumes of mix (eg, for 10 mL PiColorLock reagent add 0.1 mL Accelerator) were added. Next, it is the addition of 0.1 volumes stabilizer 5 minutes later. Finally, the plates were...
The effect of CD73 ON ERCs mediated cardiac allograft protection was examined in a study. The study included hearts from BALB/c mouse donors and C57BL/6 mouse recipients. The hearts were transplanted into the abdominal cavities of the recipients. The recipient mice were randomly assigned to three groups: untreated group, ERCs pretreated group, and ERCs with no modification. The CD73 ON ERCs were used as stimulators in cocultures with C57BL/6 mouse splenocytes. The proliferation of splenocytes was measured using the CCK-8 assay. The graft survival time was monitored, and the explanted hearts were assessed histologically and immunohistochemically.

**2.3 Cocultures of ERCs with C57BL/6 mouse splenocytes in vitro**

In order to investigate whether CD73 expression on ERCs could influence the differentiation of C57BL/6 mouse splenocytes, the splenocytes were cocultured with different ERCs (ERCs: unmodified ERCs; *ERCs: ERCs pretreated with anti-CD73 mAb) respectively in 48-well plates. At first, ERCs were resuspended and pretreated with or without anti-CD73 mAb (10 μg/mL) at 37°C for 2 hours. Subsequently, the splenocyte suspension was prepared. To be specific, the sacrificed spleens were grinded and filtered by sterilized meshes (100 meshes) individually. After the lysing of red blood cells, the remaining cells were resuspended. Then, fresh splenocytes (5 × 10⁵ cells per well), different ERCs (2.5 × 10⁵ cells per well) and various stimulators were added into the wells of 48-well plates which were placed in the 37°C 5% CO₂ incubator for 96 hours. As for the stimulators, the lipopolysaccharide (LPS, 10 μg/mL) was used for the stimulation of dendritic cells (DCs); the interleukin (IL)-4 (100 U/mL) and LPS (10 μg/mL) were the stimulator of macrophages type 2 (M2); the anti-mouse CD3 (100 ng/mL) and CD28 (200 ng/mL) antibodies were responsible for the activation of CD4⁺ T cells. Finally, the cells were examined with the help of flow cytometric analysis (n = 6).

**2.4 Animals**

Adult C57BL/6 and BALB/c mice (male, 10-12 weeks old, weighing 22-27 g) were obtained from China Food and Drug Inspection Institute (Beijing, China, http://www.nicpbp.org.cn). All animals used in this study were housed under a conventional experimental environment with enough space, water, food, and appropriate temperature at Tianjin General Surgery Institute (Tianjin, China). In addition, all animal use was under the animal use protocol approved by the Animal Care and Use Committee of Tianjin Medical University (Tianjin, China) and all the experiments were performed in accordance with the guideline of the Chinese Council on Animal Care.

**2.5 Experimental groups and allogeneic cardiac transplantation**

The C57BL/6 mouse recipients were randomly assigned to three experimental groups (n = 6): untreated group; ERCs treated group (ERCs with no modification); *ERCs treated group (ERCs pretreated with anti-CD73 mAb, 10 μg/mL). As described in our previous study, the intro-abdominal heterotopic cardiac transplantation model was adopted, in which the heart of BALB/c mouse was transplanted to the abdominal of C57BL/6 mouse recipient. After operation, the recipient mice were fed separately under appropriate conditions. The heartbeat of the grafts was recorded daily by the same member of our research team who had no idea about the treatment details. According to the force of the graft heartbeat, the pulsation was divided to three degree: A, beating strongly; B, noticeable decline in the intensity of pulsation; C, the graft heartbeat completely arrested. The harvest time of the heart grafts was at the time of rejection for the assessments of histology and immunohistochemistry. In addition, for the study of the immune cell population of the recipient mice, the splenocytes were collected at postoperative day (POD) 8.

**2.6 Histology and immunohistochemistry assessment**

After being formalin-fixed, dehydrated and paraffin-embedded, the heart graft samples were cut to slices with 5 μm thickness. Then, the sections were stained with hematoxylin and eosin (H&E). All the finished products were used to evaluate the severity of rejection with the help of a light microscope. The presence of myocyte necrosis, interstitial hemorrhage, lymphocyte infiltration, vasculitis, and intra-vascular thrombosis were detected and scored with the same criteria as described previously. To be specific, compared with normal tissues 0 means no change, 1 stands for minimum change, 2 represents mild change, 3 signifies moderate change, and 4 indicates marked change. To examine the immune cell infiltration in heart grafts of different groups, biotin-conjugated rat anti-mouse CD4 mAb and CD8 mAb (Abcam, http://www.abcam.cn) were adopted. After removing the influence of nonspecific staining by negative control sections, the infiltration of CD4⁺ and CD8⁺ cells were quantified by recognizing and calculating the positive staining areas within a given section with the help of the ImageJ software (https://imagej.net).

**2.7 Mixed lymphocyte reaction**

A one-way mixed lymphocyte reaction (MLR) was carried out to examine the function of tolerogenic DCs (Tol-DCs) through the observation of T-cell proliferative responding to alloantigen. In brief, at POD 8, the spleens of the recipient mice were harvested to collect CD11c⁺ cells by CD11c microBeads (Miltenyi, http://www.miltenyibiotec.com). Then, CD11c⁺ cells were processed with mitomycin C (50 μg/mL) (Solarbio, http://www.solarbio.net.cn). At the same time, CD3 microBeads (Miltenyi, http://www.miltenyibiotec.com) were used to select the splenic T cells of BALB/c mice. Next, the CD11c⁺ cells (5 × 10⁴ cells per well) and the CD3⁺ T cells (5 × 10⁵ cells per well) were incubated together in a 96-well plate for 96 hours in a 37°C 5% CO₂ incubator (n = 6). Finally, the proliferative response of T cells induced by the CD11c⁺ cells from different groups was measured by Cell Counting Kit-8 (CCK-8) (Dojindo, http://www.dojindo.cn). The OD value was recorded at 450 nm by the Microplate Reader.
2.8 | Flow cytometry analysis

The flow cytometry analysis was used to identify the phenotype of ERCs and detect the population of immune cells in the study. The procedure of staining was the same as described previously. In brief, the collected cells were divided to 100 μL single cell suspension and then stained with the fluorescent-labeled antibodies, which were purchased from eBioscience (http://www.thermofisher.com) and BioLegend (https://www.biolegend.com), including anti-CD105-PE-Cy7, anti-CD90-PE, anti-CD73-FITC, anti-CD39-APC, anti-CD11c-APC, anti-MHC II-FITC, anti-CD68-PE, anti-CD206-PE, anti-CD4-FITC, anti-CD25-PE, and anti-FOXP3-APC. Finally, the percentage of different cells was analyzed by the software FlowJo (https://www.flowjo.com).

2.9 | Enzyme-linked immunosorbent assay

The mouse IL-10, IFN-γ, and TNF-α ELISA kits, which were purchased from DAKEWE (China, http://www.bio-city.net), were used to measure the level of IL-10, IFN-γ, and TNF-α in the serum of recipient mice. All experimental operations were conducted under the manufacture's instruction. According to DAKEWE ELISA kit instructions, 100 μL serum sample is required for each test well, and three representative cytokines were tested in this experiment.

2.10 | Real-time PCR for gene transcription

The RNAPrep Pure Tissue Kit (Tiangen, http://www.tiangen.com) was used to extract and purify total RNA from experimental tissues. Then, the total RNA was reverse-transcribed by FastQuant RT Super Mix (Tiangen, http://www.tiangen.com) and the mRNA expression level of A2A and A2B receptors was quantified by 2× SYBR Green qPCR Master Mix (Bimake, https://www.bimake.cn). All procedures were according to the manufacture's instructions. The primer sequences included: β-actin, forward, 5'-ATAT CGCT GCGC TGGT CGTC-3', reverse: 5'-AGGA TGGC GTGA GGGA GAGC-3'; A2A receptor, forward, 5'-CGGG ATCC GTCCCTGG CCAT CATC GT-3', reverse: 5'-GGAA TTGC ATCC TGTA GGCG TAGT-3'; A2B receptor, forward, 5'-ATGC AGCT AGAG ACGC AAGA C-3', reverse: 5'-GGGA TACC AGAA AGTA GTTG GTG-3'.

2.11 | Western blot

Cardiac allograft tissues were homogenized and total protein was extracted by RIPA lysis mixed with PMSF (Solarbio, http://www.solarbio.com). Next, 50 μg of protein per sample was subjected to 7.5%, 10%, or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After incubating at 4°C with anti-A2A receptors antibody (dilution at 1:1000, Thermo Fisher Scientific, https://www.thermofisher.com), anti-A2B receptors antibody (dilution at 1:1000, Thermo Fisher Scientific, https://www.thermofisher.com) and anti-β-actin antibody (dilution at 1:2000, Servicebio, https://www.servicebio.cn) for one night, the membranes with blotted proteins were then incubated with HRP-conjugated goat anti-rabbit secondary antibody (dilution at 1:2000, Servicebio) at room temperature for an hour. After washing by TBST and add of electrochemiluminescence solution, the membranes were finally exposed to the exposure machine and the images were recorded and analyzed.

2.12 | Statistical analysis

All the collected experimental data were presented as mean ± SD and the differences between multiple groups were calculated using one-way analysis of variance (ANOVA). The survivorship curve of the heart servicebio.cn for one night, the membranes with blotted proteins were then incubated with HRP-conjugated goat anti-rabbit secondary antibody (dilution at 1:2000, Servicebio) at room temperature for an hour. After washing by TBST and add of electrochemiluminescence solution, the membranes were finally exposed to the exposure machine and the images were recorded and analyzed.

All the collected experimental data were presented as mean ± SD and the differences between multiple groups were calculated using one-way analysis of variance (ANOVA). The survivorship curve of the heart

**FIGURE 1** Characterization of ERCs and the catalytic function of its CD73 in vitro. A, The expression of cell markers on the surface of ERCs measured by flow cytometry analysis. Most of ERCs could express CD105 (99.7%), CD90 (98.6%), and CD73 (98.4%), but they were negative for the cell marker CD39 (2.1%). B, The green fluorescent staining reflected that CD73 expressed on the membrane of ERCs. C, The catalytic ability of CD73 was quantified by the measurement of free Pi generated by the hydrolysis of AMP. Statistical analysis was done by one-way ANOVA, n = 6, P < .001 (ERCs vs **ERCs: 79.55 ± 0.39 μM vs 9.841 ± 0.13 μM). ERCs, endometrial regenerative cell; **ERCs, ERCs pretreated with anti-CD73 mAb; **ERCs, ERCs pretreated with anti-CD73 isotype mAb; GFP, green fluorescent protein; ANOVA, analysis of variance; ***P < .001.
graft was conducted by Kaplan-Meier cumulative survival method and the differences among groups were analyzed by log-rank (Mantel-Cox) test. It was considered significant that differences with \( P \leq .05 \).

3 | RESULTS

3.1 | CD73 highly expressed on the surface of mesenchymal-like ERCs and showed effective catalytic activity in vitro

To evaluate the catalytic activity (which is converting AMP to ADO) of CD73 anchored on the surface of ERCs in vitro, we performed a series of experiments. As shown in Figure 1A, the results of the flow cytometry analysis revealed that ERCs could express CD105 (99.7%), CD90 (98.6%), and CD73 (98.4%), but they were negative for CD39 (2.1%). The phenotype of ERCs was consistent with that of the MSCs. In addition, to make the expression of CD73 of ERCs more intuitive, the fluorescence staining was conducted. The green fluorescent staining reflected that CD73 expressed on the membrane of ERCs (Figure 1B). Furthermore, the catalytic activity of CD73 was quantified through counting the free Pi, which was the by-product of the dephosphorylation of AMP. To realize our purpose, the research was designed into three groups: ERCs group (unmodified ERCs); *ERCs group (ERCs pre-treated with anti-CD73 mAb); **ERCs group (ERCs pre-treated with anti-CD73 isotype mAb). Figure 1C presented the concentration of the free Pi among different groups. When compared with ERCs group and **ERCs group, the level of free Pi was significantly decreased in the *ERCs group (ERCs vs *ERCs: 79.55 ± 0.39 \( \mu \)M vs 9.841 ± 0.13 \( \mu \)M, \( P < .001 \); **ERCs vs *ERCs: 77.62 ± 2.01 \( \mu \)M vs 9.841 ± 0.13 \( \mu \)M, \( P < .001 \)). While, there was no significance between ERCs group and **ERCs group (\( P = .20 \)). The data indicate that ERCs are a kind of mesenchymal-like cells and most of them express CD73 which is critical for ERCs in the process of converting AMP to ADO.

3.2 | CD73 expressing ERCs suppressed the generation of mature DCs and promoted the differentiation of M2 and regulatory T cells (Tregs) in vitro

To determine the impact of CD73 expression have on the ERCs in regulating the immune cells in vitro, coculture of ERCs with C57BL/6...
mouse splenocytes was conducted for counting the population of mature DCs (CD11c+CD86+ and CD11c+MHCII+), M2 (CD68+CD206+), and Tregs (CD4+CD25+Foxp3+) by flow cytometry analysis. As for the abbreviations in Figure 2 and Figure 3, Sp represented for splenocytes and St represented for stimulators. Figure 2A showed the percentage of the same DCs in two group of cell markers. The statistical analysis was shown in Figure 2B,C. Compared to the Sp + St group, the addition of ERCs significantly decreased the percentage of mature DCs (Sp + St vs Sp + St + ERCs: CD11c+CD86+, P < .001; CD11c+MHCII+, P < .01). When the CD73 was blocked by the anti-CD73 mAb, the inhibitory function of ERCs was significantly downregulated (Sp + St + ERCs vs Sp + St + *ERCs: CD11c+CD86+, P < .01; CD11c+MHCII+, P < .05). As shown in Figure 3A,B, with the blockade of CD73 on ERCs, the percentages of M2 and Tregs were markedly decreased in the Sp + St + *ERCs group as compared to the Sp + St + ERCs group (M2: P < .001; Treg: P < .05). These data suggest that CD73 expression is essential for ERCs in regulating immune cells in vitro.

3.3 | CD73 expressing ERCs significantly prolonged cardiac allograft survival

To investigate the effects of CD73 expression for ERC-mediated prolongation of cardiac allografts, the recipient mice were treated with either normal ERCs or ERCs pretreated with anti-CD73 mAb. It has been found that CD73 expression on ERCs could significantly prolong allograft survival. As shown in Figure 4A, the allograft survival time significantly prolonged in the ERCs group (untreated vs ERCs: 7.50 ± 1.05 days vs 20.00 ± 1.55 days, P < .001). Once the CD73 was blocked, the allograft survival time was markedly shortened (ERCs vs *ERCs: 20.00 ± 1.55 days vs 13.17 ± 1.85 days, P < .001).

The graft pathology (Figure 4B) revealed that the grafts in untreated group showed severe rejection with vasculitis and massive cells infiltration. ERCs treatment could significantly attenuate the lesion and showed almost normal pathology. However, blocking CD73 apparently reduced the effect of ERCs in mediating allograft protection, and the grafts had severe damage (The pathological score...
ERCs vs *ERCs: P < .05, data not shown). The intragraft CD4+ and CD8+ cell infiltrations which reflect the acute cellular rejection were shown in Figure 4E,F. The pictures mainly include myocardial cells and lymphocytes. Figure 4E showed that the intragraft CD4+ cell infiltration was the most serious in the untreated group and the lightest in the ERCs group. CD8+ cell infiltration shared the same trend with the CD4+ cell infiltration. For statistical analysis, the brownish black positive areas which represent CD4+ cells or CD8+ cells were recognized and calculated by the ImageJ software. The immunohistochemistry assessment displayed that unmodified ERCs could attenuate the infiltration of CD4+ (ERCs vs *ERCs: 0.21% ± 0.02% vs 0.68% ± 0.03%, P < .01) and CD8+ (ERCs vs *ERCs: 0.87% ± 0.13% vs 2.23% ± 0.14%, P < .001) cells, compared to the *ERCs group (Figure 4C,D). These results highlight that ERC treatment is able to significantly prolong cardiac allograft survival and CD73 expression is critical in this process.

3.4 CD73 expressing ERCs decreased the percentage of mature DCs and enhanced the function of Tol-DCs in transplant recipients

To determine the population and function of DCs influenced by the CD73 expressed on ERCs in spleens of transplant recipients, the flow cytometry analysis and one-way MLR were performed. Figure 5A-C displayed that the percentage of mature DCs (two group of markers: CD11c"CD86" and CD11c"MHC II") in both ERCs group and *ERCs group were lower than that in the untreated group (ERCs vs untreated: CD11c"CD86", P < .01; CD11c"MHC II", P < .001; *ERCs vs untreated: CD11c"CD86", P < .01; CD11c"MHC II", P < .05). However, the blockade of CD73 significantly increased the percentage of mature DCs compared to that of ERCs group (ERCs vs "ERCs: CD11c"CD86", P < .01; CD11c"MHC II", P < .01). In addition, tolerance of the DCs (which is the function of Tol-DCs) could be reflected by the proliferation of antigen-
stimulated CD3+ T cells. So, in this research, the promoting proliferation ability of mitomycin C processed CD11c+ DCs (obtained from post-operative C57BL/6 recipients) to antigen-stimulated CD3+ T cells (isolated by CD3 microBeads from the splenocytes of the BALB/c mice) was measured by the OD value. Briefly, the OD value represented the proliferation index of CD3+ T cells, which is related to the degree of the CD11c+ DCs stimulus. As shown in Figure 5D, compared with the untreated group, the CD3+ T-cell proliferation index was lower in the *ERCs group (*ERCs vs untreated: \(P < .001\)) and further lower in the ERCs group (ERCs vs untreated: \(P < .001\)). As expected, there was also a significant difference between the ERCs and *ERCs group (ERCs vs *ERCs: 0.22 ± 0.01 vs 0.26 ± 0.01, \(P < .01\)). In addition, the lower proliferation index of CD3+ T cells presented the higher tolerance of the CD11c+ DCs. In one word, CD73 expression is critical for ERCs in decreasing the generation of mature DCs and promoting the tolerance of the DCs.

3.5 CD73 expressing ERCs reduced the percentage of total macrophages but increased the percentage of M2 and Tregs in transplant recipients

To identify the population of macrophages and Tregs in the cardiac allograft recipients, the CD68 and CD206 antibodies staining was introduced to mark the macrophages and the triple-positive staining of CD4, CD25, and Foxp3 antibodies was used to mark the Tregs. CD68+ staining positive represented the total macrophages, compared to the ERCs group, the percentage of the total macrophages was higher in the untreated group (untreated vs ERCs: \(P < .01\)) and lower in the *ERCs group (Figure 6F; \(P < .05\)). The population of CD68+CD206+ M2 was highest in the ERCs group (Figure 6G; ERCs vs untreated, \(P < .05\); ERCs vs *ERCs, \(P < .05\)). Similarly, as shown in Figure 6B,H, ERCs significantly increased the population of the Tregs compared to that of untreated group (untreated vs untreated, \(P < .001\)). However, when the CD73 was blocked, the ability of ERCs in enhancing Tregs was significantly downregulated (ERCs vs *ERCs, \(P < .01\)).

3.6 CD73 expressing ERCs reduced the secretion of IFN-γ and TNF-α, and increased the levels of IL-10 in the recipient serum

To examine the levels of the inflammatory cytokines in the cardiac allograft transplantation model, the IFN-γ, TNF-α, and IL-10 ELISA kit were adopted, and we found that samples in the ERCs group expressed the lowest level of pro-inflammatory cytokines IFN-γ (ERCs vs untreated, \(P < .001\); ERCs vs *ERCs, \(P < .05\)) and TNF-α (ERCs vs *ERCs, \(P < .001\)).
untreated, *P < .05; ERCs vs untreated, **P < .01; ERCs vs *ERCs, ***P < .001; Figure 7A,B), and the ERCs group expressed the highest level of anti-inflammatory cytokine IL-10 (ERCs vs untreated, *P < .01; ERCs vs *ERCs, **P < .05; Figure 7C). Interestingly, the *ERCs group still shown a decrease secretion of IFN-γ (*P < .05) and TNF-α (**P < .01), and an increase secretion of IL-10 (**P < .01), compared to the untreated group.

### 3.7 | CD73 expressing ERCS downregulated the expression of tissue A2A receptors and upregulated the expression of tissue A2B receptors in allografts

ADO is the final product in purine metabolism that is able to combine with ADO receptors and express various biological functions. To determine the expression of ADO related A2A and A2B receptors in the allografts, the mRNA transcription of A2A and A2B receptors was quantified by Real-Time PCR. As shown in Figure 7D, the mRNA expression of A2A receptors was much higher in the allografts of untreated group and was significantly reduced in cardiac allografts of ERCs group and *ERCs (untreated group vs ERCs group, ***P < .001; untreated group vs *ERCs group, **P < .01). However, the mRNA transcription of A2A receptors in allografts was markedly increased when CD73 expression was blocked on ERCs (ERCs group vs *ERCs group, **P < .01). However, as performed in Figure 7E, the mRNA expression of A2B receptors was markedly inhibited by the blocking of CD73 on ERCs (ERCs vs *ERCs, **P < .01). In addition, Figure 7F-H showed the amount of protein of A2A receptors and A2B receptors. Figure 7G showed that the expression of A2A receptors was highest in the untreated group and lowest in the ERC group (untreated group vs ERCs group, *P < .05; untreated group vs *ERCs group, **P < .01; ERCs group vs *ERCs group, ***P < .001). As for the expression of A2B receptors, it was highest in the ERCs group and lowest in the untreated group (untreated group vs ERCs group, **P < .01; untreated group vs *ERCs group, ***P < .001; ERCs group vs *ERCs group, **P < .01; ERCs group vs *ERCs group, **P < .01;
DISCUSSION

Nowadays, organ transplantation has become the ultimate method for some of end-stage diseases. Despite the brilliant development prospect of organ transplantation, there are two major challenges remain to be overcome, namely the shortage of donor organs and the immunological rejection. Facing the two difficult challenges, on the one hand, efforts should be made to increase the pool of available donor organs. On the other hand, further research needs to be done on inhibiting immunological rejection to prolong the graft survival time, aiming to reduce organ demand. Both our previous studies and the present study show that ERCs are able to prolong cardiac allograft survival.20,21 The combination of ERC-based therapy with rapamycin can even achieve long-term survival.21 So, it indicates that ERCs are potential immunosuppressive agents.

However, the exact mechanism of ERCs in immunoregulation is still a puzzle. Thus, the current study was undertaken to determine the role of CD73 expression in mediating ERC-induced cardiac allograft protection. CD73 is a key enzyme in purinergic signaling with the function of converting AMP to ADO and has been proven to be involved in several physiological and pathological processes by a growing body of researches.43 Apart from the expression on ERCs, CD73 is widely distributed in various tissues and cells including heart tissues and immune cells.31,44 More importantly, the function of CD73 can be well inhibited by three methods.45 In this study, the free Pi concentration decrease in the CD73 blocking ERCs group proved that anti-CD73 mAb completely blocked the expression of CD73 on ERCs. In addition, the CD73 blocking ERCs also showed significant reduction in immunoregulation and graft protection in this cardiac transplant model.
First, we found that CD73 expression is critical for ERCs in reducing the mature DCs and enhancing the function of Tol-DCs. As we all know, acute rejection is the most common type of rejection in solid organ transplantation. At the same time, the antigen-presenting cells are critical in presenting foreign antigens to the recipient CD4+ and CD8+ T cells, which is one of the initiating factors in the activation of adaptive immune system. Through our data, we can infer that ERCs are able to increase the concentration of ADO in local microenvironment via the dephosphorylation of AMP and the blockade of CD73 will lower the level of ADO. While the maturation of DCs is connected to the expression of ADO receptors, early evidence shows that immature DCs can express A2 and A3 receptors and the A2 receptors activation will trigger a powerful chemotactic effect, which promotes the immature DCs migrate to the inflamed tissue. On the condition of high concentration of ADO, the expression of A1 receptors reduces on the surface of immature DCs, but the expression of A2 receptors changes in an opposite direction. This new phenotype of the DCs is called Tol-DCs that hardly activate T cells and are able to inhibit the production of pro-inflammatory cytokines. That is to say, the by-product of ADO generation by CD73 inhibits the maturation of DCs. Further studies have also demonstrated the inhibiting maturation effect of ADO to DCs and promoting the polarization of DCs to a tolerogenic phenotype. In addition, in this study, we observe an increase secretion of IL-10 and a decrease secretion of IFN-γ in the serum of recipients. This may relate to the enhanced function of Tol-DCs which cannot activate adaptive immune system proved by the one-way MLR.

Second, we also found that CD73 expression is vital for ERCs in reducing the total macrophages and promoting the polarization to M2. Similar to the DCs, macrophages are another type of antigen-presenting cells in the innate immune system, the differentiation and maturation of which are critical in activating adaptive immune cells. When the monocytes enter injured tissues, they can polarize in two opposite directions: pro-inflammatory macrophages (M1) and anti-inflammatory macrophages (M2). The M2 can perform a tissue protection function by inhibiting secretion of TNF-α and promoting secretion of IL-10. The TNF-α secretion also decreases in our study in the group treated with ERCs. However, when the CD73 is blocked, the level of TNF-α increases significantly which is consistent to the polarization change of macrophages. Moreover, macrophages can regulate inflammation response via the expression of ADO receptors. At first, inflammation can upregulate the expression of some ADO receptors. For example, LPS upregulates A2A receptors in primary murine peritoneal and bone marrow-derived macrophages and RAW264.7. Then, the activation of A2A receptors performs an anti-inflammation function. Further study indicates that not only do A2A receptors contribute to ADO regulation, but A2B receptors make a contribution.

Third, Tregs also play a key role in prolonging cardiac allograft survival. Similar to previous studies, we have also found that CD73-expressing ERCs significantly increased the percentage of Tregs population. However, blocking CD73 expression on ERCs markedly reduces the population of Tregs. The mechanism may also due to the metabolism of ADO. Schenk et al reported that the ATP receptors P2X-R mediated the polarization of T cell into Th17 cells. However, pharmacological block of the P2X-R would lead the naïve CD4+ T cells polarize to Tregs. It indicates that the decreased concentration of ATP in the local microenvironment is related to the upregulation of Tregs. However, when the ERCs were adopted, the ADO genesis function of CD73 would decrease the concentration of local ATP by a series of sequential reactions and result in the increase of Tregs. In addition, it has been demonstrated that mouse Tregs could reduce the concentration of ATP in the local microenvironment by themselves via expressing CD39 and CD73, which in turn promotes the differentiation of Tregs. Apart from this, the interaction of generated ADO with A2AR has been proven to inhibit immune response directly and instantly. Further study also showed that the ADO-A2A receptor signaling played a key role in maintaining the CD73 and programmed cell death protein 1 expression on the surface of Tregs. If the A2A receptor was deleted, the immunosuppressive activity would decrease significantly related to the function loss of CD73 and programmed cell death protein 1. What’s more, Tregs were found to secrete exosomes containing CD39 and CD73, which took part in the suppressing of effector T cell proliferation and IL-2 secretion. In conclusion, the CD73 expression on ERCs is able to induce the generation of Tregs and performs an immunosuppression effect, in which the activation of A2AR is necessary.

It is well known that the heart tissue can express the four ADORs, some of them conduct a heart protective effect in certain conditions. We also find a change in the expression of A2A and A2B receptors in our study. Previous study displays that the A2AR activation does lots of benefits in coronary occlusion by inhibiting the infiltration of CD4+ cells in the reperfused heart. The decreased infiltration of CD4+ and CD8+ cells in our study supports this view well. However, the expression of A2A receptors decreases in the ERCs group which seems to be contrary to the tissue protection function of them. Actually, it may due to at this timing the activation of A2A receptors just plays a secondary role. In addition, the activation of A2B receptor also performed a heart protect function. For example, in the research of murine cardiac allograft vasculopathy, activation of A2B receptor resulted in marked prolongation of graft survival and it has been demonstrated that activation of A2B receptors could against hypoxic injury. In our study, we observed an increase expression of A2B receptors at the time of POD 8. The data imply that the high expression of A2B receptors may contribute to the cardiac allograft protection.

Given the homology between human CD73 and mouse CD73, the increasing evidence showed the therapeutic effects of human-derived stem cells on different xenogeneic models. Although we use human ERCs to coculture with mouse cells and treat a mouse model, we speculate that full ERCs effects could be preserved in this xenogeneic setting and the xenogeneic setting would have similar effect as an allogeneic combination. In this study, we have demonstrated that CD73 expression on ERCs played an important role in cardiac allograft protection through three aspects. First and foremost, CD73 expression had an influence on the immune system and induced the immune condition develop.
toward a graft protection way. Second, CD73 expression on ERCs was able to increase the concentration of anti-inflammatory cytokines and reduce the concentration of pro-inflammatory cytokines. Last but not least, CD73 expression on ERCs also performed tissue protection function via the regulation of tissue expression of ADO receptors. This research has elucidated the function of CD73 expression on ERCs clearly. We also inspired by the results that enhancing the expression of CD73 could augment the immunoregulation function of ERCs on achieving long-term allograft acceptance, and underlying in-depth studies on ERCs are warranted.

5 | CONCLUSION

The newly identified ERCs play an important role in immunoregulation. CD73 expression is critical for ERCs in mediating inhibition of transplant rejection and prolongation of cardiac allograft survival. The results obtained from this study form the basis for the precise clinical use of ERCs in transplantation.

ACKNOWLEDGMENTS

This work was supported by grants to Hao Wang from National Natural Science Foundation of China (81471584 and 81273257), Tianjin Application Basis and Cutting-Edge Technology Research Grant (14JCZDJC35700), Li Jieshou Intestinal Barrier Research Special Fund (LJS_201412), National Science Foundation of Tianjin (18JCZDJC35800), Tianjin Medical University Talent Fund, and Tianjin Research Innovation Project for Postgraduate Students to Dejun Kong (2019YJSS184).

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

Y.H.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; D.K., Y.Q.: collection and assembly of data, data analysis and interpretation, manuscript writing; D.Y., W.J., X.L., Y.Z.: collection of data, data analysis and interpretation, manuscript writing; Hongda Wang, J.H., G.L., B.Z., Z.P.: collection of data, manuscript writing; Hao Wang: conception and design, financial support, administrative support, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT

All the data generated or analyzed during this study are included in this published article.

ORCID

Yonghao Hu https://orcid.org/0000-0002-5319-1184
Yiming Zhao https://orcid.org/0000-0003-4326-9790

REFERENCES

1. Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2018 annual data report: heart. Am J Transplant. 2020;20(Suppl s1):340-426.
2. Kwong A, Kim WR, Lake JR, et al. OPTN/SRTR 2018 annual data report: liver. Am J Transplant. 2020;20(Suppl s1):193-299.
3. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2018 annual data report: kidney. Am J Transplant. 2020;20(Suppl s1):20-130.
4. Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation—the balance between under- and over-immunosuppression. Transplant Rev (Orlando). 2015;29(3):181-189.
5. Jovana C, Sladjana U, Ivan J, et al. Viral infection in renal transplant recipients. Sci World J. 2012;2012:1-18.
6. Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511-519.
7. Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015;28(1):10-21.
8. Zhang R, Ma J, Han J, Zhang W, Ma J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. Am J Transl Res. 2019;11(10):6275-6289.
9. Shigemoto-Kuroda T, Oh JY, Kim D-K, et al. MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis. Stem Cell Rep. 2017;8(5):1214-1225.
10. Dong R, Liu Y, Yang Y, et al. MSC-derived Exosomes-based therapy for peripheral nerve injury: a novel therapeutic strategy. Biomed Res Int. 2019;2019:6458237.
11. Lohan P, Murphy N, Treacy O, et al. Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation. Front Immunol. 2018;9:2666.
12. He Y, Zhou S, Liu H, et al. Indoleamine 2,3-dioxigenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells. Transplantation. 2015;99:1829-1838.
13. Eggenhofer E, Popp FC, Mendicino M, et al. Heart grafts tolerated through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. STEM CELLS TRANSLATIONAL MEDICINE. 2013;2(8):595-606.
14. Perico N, Casiraghi F, Gottli E, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int. 2013;26(9):867-878.
15. Li X, Lan X, Zhao Y, et al. SDF-1/CXCR4 axis enhances the immunomodulation of human endometrial regenerative cells in alleviating experimental colitis. Stem Cell Res Ther. 2019;10(1):204.
16. Meng X, Ichim TE, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007;5(1):57-50.
17. Zhao Y, Lan X, Wang Y, et al. Human endometrial regenerative cells attenuate bleomycin-induced pulmonary fibrosis in mice. Stem Cells Int. 2018;2018:3475137.
18. Shi G, Wang G, Lu S, et al. PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice. Am J Transl Res. 2019;11(8):4696-4712.
19. Sun P, Liu J, Li W, et al. Human endometrial regenerative cells attenuate renal ischemia reperfusion injury in mice. J Transl Med. 2016;14:28.
20. Xu X, Li X, Gu X, et al. Prolongation of cardiac allograft survival by endometrial regenerative cells: focusing on B-cell responses. STEM CELLS TRANSLATIONAL MEDICINE. 2017;6(3):778-787.
21. Lan X, Wang G, Xu X, et al. Stromal cell-derived factor-1 mediates cardiac allograft tolerance induced by human endometrial regenerative cell-based therapy. STEM CELLS TRANSLATIONAL MEDICINE. 2017;6(11):1997-2008.
22. Zhong Z, Patel AN, Ichim TE, et al. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med. 2009;7:15.
23. Meng X, Ichim TE, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007;5:57.
24. Hida N, Nishiyama N, Miyoshi S, et al. Novel cardiac precursor-like cells from human menstrual blood-dersed mesenchymal cells. 2008; 26(7):1695-1704.
25. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant. 2008;17(3):303-311.

26. Patel AN, Silva F. Menstrual blood stromal cells: the potential for regenerative medicine. Regen Med. 2008;3(4):443-444.

27. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.

28. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR.

29. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine-5'-monophosphate to adenosine. J Immunol. 2006;177(10):6780-6786.

30. Hasegawa T, Bouïs D, Liao H, et al. Ecto-5'-nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res. 2008;103(12):1410-1421.

31. Bours MJL, Swennen ELR, Di Virgilio F, et al. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112(2):358-404.

32. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. 2016;29:7-16.

33. Terp MG, Olesen KA, Arnspang EC, et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by targeting CD73 on cancer cells. Front Immunol. 2011;4:162.

34. Chen C-J, Chang S-J. Purinergic signaling during inflammation. Cell Transplant. 2008;17(3):303-311.

35. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of inducible factors and adenosine A2A receptors*. Annu Rev Immunol. 2004;22(1):657-682.

36. Resta R, Hooker SW, Hansen KR, et al. Murine ecto-5'-nucleotidase (CD73): cDNA cloning and tissue distribution. Gene. 1993;133(2):171-177.

37. Xu X, Li X, Gu X, et al. Prolongation of cardiac allograft survival by short-term treatment with LF15-0195 and monoclonal antibody targeting CD73 on cancer cells. Front Immunol. 2013;4(9):2430-2440.

38. Wang H, Hoshiawa KA, Min W, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol. 2003;171(7):3832-3836.

39. Wang H, Hoshiawa KA, Garcia B, et al. Attenuation of acute xenograft rejection by short-term treatment with LF15-0195 and monoclonal antibody against CD45RB in a rat-to-mouse cardiac transplantation model. Transplantation. 2003;75(9):1475-1481.

40. Wang H, Qi F, Dai X, et al. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol. 2014;31(2):65-74.

41. Morandi F, Horenstein AL, Rizzo R, et al. The role of extracellular adenosine generation in the development of autoimmune diseases. Mediators Inflamm. 2018;2018:7019398.

42. Burnstock G, Pelleg A. Cardiac purinergic signalling in health and disease. Purinergic Signal. 2015;11(1):1-46.

43. Adzic M, Nedeljkovic N. Unveiling the role of ecto-5'-nucleotidase/CD73 in astrocyte migration by using pharmacological tools. Front Pharmacol. 2018;9:153.

44. Bharat A, Mohanakumar T. Allopeptides and the alloimmune response. Cell Immunol. 2007;248(1):31-43.

45. Hofer S, Ivansson L, Stoitzner P, et al. Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol. 2003;121(2):300-307.

46. Resta R, Yamashita Y, Thompson LF, Karhausen J, et al. Murine ecto-5'-nucleotidase/CD73 in astrocyte migration by using pharmacological tools. Front Pharmacol. 2018;9:153.
cardiomyopathy in a porcine model. Transplantation. 2018;102(12):2012-2024.

67. Chen X, Cai C, Xu D, et al. Human mesenchymal stem cell-treated regulatory CD23(+)CD43(+) B cells alleviate intestinal inflammation. Theranostics. 2019;9(16):4633-4647.

68. Xiang B, Chen L, Wang X, et al. Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci. 2017;18(4):689.

How to cite this article: Hu Y, Kong D, Qin Y, et al. CD73 expression is critical to therapeutic effects of human endometrial regenerative cells in inhibition of cardiac allograft rejection in mice. STEM CELLS Transl Med. 2021;10:465–478. https://doi.org/10.1002/sctm.20-0154